ReneuBio

small molecules, neural stem cells, aged brain screening

repairingsmall molecule

reneubiotx.com·San Diego, California, United States·

01Overview 02People 03Projects 04Concepts 05Patents 06Public records 07Belief evolution

Plate C · C-VLCM

Projects

Aging Brain Neural Stem Cell Reactivation Therapeutics

preclinical

drug program · high

Develop medicines for age-related brain disorders by restoring the aging brain's ability to heal through reactivation of dormant neural stem cells, with mentioned disease areas including chemobrain, stroke, and Alzheimer's disease.

Small-molecule therapeutic development targeting regenerative capacity in the aging brain and neural stem cell reactivation.

Company describes an active therapeutic mission and chemistry effort, but no named candidate, trial, or pipeline stage is disclosed.

Target Discovery Engine

exploratory

platform · high

Identify therapeutic targets directly in aged brain tissue to support development of small-molecule therapeutics for the aging brain.

Screening old cells and old brains to identify targets in aged brain tissue; described as the company's innovation engine.

Ruetz et al. Nature 2024 is listed as the publication for the Target Discovery Engine, and Tyson Ruetz is described as its developer and lead author.

The supplied material states the platform screens old cells and old brains to identify therapeutic targets, but does not provide detailed experimental results.

Loading

Loading section...

0-100 chain-logic scale · 15 dimensions · scored on public evidence